Comparing two strategies to increase HIV self-testing among social networks of PrEP clients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the effectiveness of two different social network strategies—direct distribution and referral-based distribution—in enhancing the completion rates of HIV self-testing (HIVST) among individuals connected to current Pre-Exposure Prophylaxis (PrEP) clients. Participants, known as 'Egos', will identify peers in their social networks who may benefit from HIVST kits and PrEP information. The study will involve PrEP clients who are currently receiving treatment and their identified peers, referred to as 'Alters'. The goal is to improve access to HIV testing and prevention methods within these networks.

Why it matters

Who can join: the full rules

Inclusion Criteria - PrEP Clients (Egos):

* Stated willingness to provide informed consent.
* Stated willingness to comply with all study procedures.
* Stated availability for the duration of the study.
* Ability to identify members of their social network who may benefit from receiving an HIVST kit and PrEP information.
* Currently prescribed PrEP by RAPID clinics, including those initiating PrEP on the same day as study enrollment.

Inclusion Criteria for Peers (Alters):

\- Provision of electronic informed consent prior to completion of the Quick Response (QR)-linked survey instruments.

Exclusion Criteria for PrEP Clients (Egos):

* Inability or refusal to provide informed consent (e.g., cognitive impairment).
* Unable or unwilling to comply with study procedures per study investigator
* Inability to identify members of their social network who may benefit from receiving an HIVST kit and PrEP information.
* Aged 17 years or younger.

Exclusion Criteria for Peers (Alters):

* Failure to provide electronic informed consent prior to starting QR-linked Alter survey tools.
* Age 17 years or younger.

Where it's running

• University of Miami
  Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Susanne Dobleck-Lewis, MD — University of Miami
• Study coordinator: Susanne Doblecki-Lewis, MD
• Email: SDoblecki@med.miami.edu
• Phone: 3052434037

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Camino HIV Prevention and Care Study

  This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.

  Recruiting American University · Berkeley, California and 1 other locations · NCT07834853

• VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body

  This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.

  Recruiting at 2 sites Phase 1 ViiV Healthcare · Glendale, California and 1 other locations · NCT07818915

• Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use

  In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.

  Recruiting Oswaldo Cruz Foundation · Rio de Janeiro, Rio de Janeiro · NCT07772791

• Metabolic Liver Disease in People Newly Diagnosed with HIV

  This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.

  Recruiting at 11 sites Guven Health Group · Ankara, Ankara and 10 other locations · NCT07737340

• Screen2Prevent: HIV screening for teens and young adults in emergency departments

  The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.

  Recruiting at 5 sites Westat · Tampa, Florida and 4 other locations · NCT07728123

• Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART

  This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.

  Recruiting at 19 sites Phase 3 Gilead Sciences · San Francisco, California and 18 other locations · NCT07682961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.